0
     

Report Added
Report already added
Lutetium-177 (Lu-177) Global Market and Pipeline Analysis – Forecast To 2028

Lutetium-177 (Lu-177) Global Market and Pipeline Analysis – Forecast To 2028

“Lutetium-177 (Lu-177) Global Market and Pipeline Analysis – Forecast to 2028” gives comprehensive insights on the various Lu-177 based drugs being developed for the treatment of developed for the treatment of prostate cancer, NETs, Lung cancer, solid tumors and other conditions. The report covers marketed products details and also drugs that are in various phases of development (Discovery, Preclinical & Clinical). The pipeline focuses on Lu-177 labeled monoclonal antibodies and peptides for various indications that are in clinical trials, FDA and CE approved products.

The report covers the patient population, treatment cost, total addressable market and penetration analysis for GEP-NET and Prostate cancer. It covers list of nuclear reactors that have potential to produce Lu-177 both medium and high flux reactor with their locations all over the world. It also focuses on supply chain analysis and market dynamics (DROT) of Lu-177.

This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Lu-177 global market. The report also provides strategic insights on some of the molecules which will eventually be launched in the next few years.

Market Analysis
In market analysis section, global GEP-NET and Prostate cancer market are indicated along with the Lu-177 therapy market size, eligible patients pool, total addressable market (TAM), market penetration, opportunity and demand for Lu-177 isotope is forecasted from 2019 to 2026.
Lu-177 players and their production capacities
Lu-177 market dynamics.
Lu-177 related deals analysis.
Global, N.A., Europe, APAC and RoW prevalence rates (GEP-NET & Prostate cancer).

Pipeline Analysis
Pipeline Analysis based molecule type
Pipeline Analysis based on indications
Pipeline analysis based on targets
Monoclonal Antibodies labeled pipeline analysis
Peptide labeled pipeline analysis
Pipeline analysis based on leading players & their molecule analysis

Key Players Analysis
The key player’s analysis section provides an in-depth understanding of various companies working on Lu-177 and their pipelines with development phase as well as understanding partnering strategies such as deals entered by the company.
Global key players overview
Global key players Pipeline data (discovery, pre-clinical & clinical development)
Global key players deal (collaborations, partnership, licensing agreements, grants, funding etc.)

Table of Contents

REPORT DESCRIPTION INTRODUCTION
EXECUTIVE SUMMARY
MARKET DYNAMICS (DROT)
SUPPLY CHAIN ANALYSIS
• Direct
• Indirect
SUPPLY CHAIN UPDATES
• Major Suppliers
• U.S. DMF Filing Details
Lu-177 ANNUAL ESTIMATED PRODUCTION CAPACITY IN Ci (SELECTED REACTORS)
PRODUCTION COST OF DIRECT/INDIRECT METHOD
DEALS
• Agreement
• Partnership
• Collaboration
MARKET DATA
• TAM and Penetration - GEP-NET (Region)
• TAM -Prostate Cancer (Region)
ASSUMPTIONS
PIPELINE ANALYSIS
• Development Stage
• Indications
• Targets
• Major Players
• Molecule Type
RIT BASED PIPELINE ANALYSIS
• By Phase
• By Indication
• By Target
• Pipeline Analysis
• Clinical trial update on Phase 3 and Phase 2b molecules PRRT BASED PIPELINE ANALYSIS
• By Phase
• By Indiacation
• By Target
• Pipeline Analysis
• Clinical trial update on Phase 3
MAJOR PLAYERS
• Company Profiles
• Overview, Pipeline
MEDIUM FLUX REACTOR AND LOCATION
HIGH FLUX REACTOR AND LOCATION
REFERENCES
DISCLAIMER

Report Title: Lutetium-177 (Lu-177) Global Market and Pipeline Analysis – Forecast To 2028


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

Genome-Based Drug Companies in China

Genome-Based Drug Companies in China

Biologics Companies in China

Biologics Companies in China

Bladder Cancer Treatment Drugs Companies in China

Bladder Cancer Treatment Drugs Companies in China

Health Care  Companies in China

Health Care Companies in China

Cardiovascular Drugs Companies in China

Cardiovascular Drugs Companies in China

Cancer Treatment Drugs Companies in China

Cancer Treatment Drugs Companies in China